On Thursday, First Bancorp (NYSE:FBP)’s shares declined -3.07% to $4.74.
First BanCorp (FBP), the bank holding company for FirstBank Puerto Rico, is happy to declare the results of its 2015 company-run capital stress test (“Dodd-Frank Act Stress Test” or “DFAST”). First BanCorp is required to disclose the results of the DFAST annually, startning with the 2015 test.
Results indicate that, even in the severely adverse scenario presented by the test, First BanCorp’s capital ratios exceed both the regulatory minimum required ratios mandated under Basel III and the well-capitalized thresholds throughout the nine-quarter time horizon.
First BanCorp. operates as the bank holding company for FirstBank Puerto Rico that provides a range of financial products and services to retail, commercial, and institutional clients. Its Commercial and Corporate Banking segment offers commercial real estate and construction loans, and floor plan financings; and cash administration and business administration services, in addition to underwrites bonds and financial advisory services offered to government entities.
Endo International plc - Ordinary Shares (NASDAQ:ENDP)’s shares gained 1.40% to $82.02.
Endo International plc (ENDP) declared that (1) its wholly-owned auxiliaries, Endo Finance LLC and Endo Finco Inc., will, subject to the satisfaction of the condition described below, redeem all $481,894,000 aggregate principal amount outstanding of their 7.00% Senior Notes due 2019 (CUSIP Nos. 29271L AB0, U2918V AB1) (the “2019 Endo Finance Notes”) on July 24, 2015 and (2) its wholly-owned partner, Endo Health Solutions Inc. (“EHSI”), will, subject to the satisfaction of the condition described below, redeem all $17,981,000 aggregate principal amount outstanding of its 7.00% Senior Notes due 2019 (CUSIP No. 29264F AG1) (the “2019 EHSI Notes” and, together with the 2019 Endo Finance Notes, the “Notes”) on July 24, 2015. Each of the redemptions is conditional and subject to the delivery of moneys sufficient to pay the applicable redemption price to Wells Fargo Bank, National Association, 150 East 42nd Street, 40th Floor, New York, New York 10017, as trustee under the indentures governing the Notes (the “Trustee”) on the redemption date.
Endo International plc, a specialty healthcare company, focuses on branded and generic pharmaceuticals and devices worldwide. It operates through four segments: U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment provides various branded prescription products, counting Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Fortesta Gel, Supprelin LA, Valstar, Vantas, Sumavel DosePro, Aveed, and Natesto to treat and manage pain and conditions in urology, endocrinology, and oncology. The U.S. Generic Pharmaceuticals segment offers products in the pain administration, urology, CNS disorders, immunosuppressant, oncology, womens health, hypertension, generic lidocaine patch, and other markets.
At the end of Thursday’s trade, Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s shares dipped -5.17% to $21.27.
Momenta Pharmaceuticals, Inc. (MNTA) declared that Sandoz has initiated its U.S. launch of once daily Glatopa(TM) (glatiramer acetate injection), a generic equivalent of daily COPAXONE(R) 20 mg, developed under a partnershipagreement between Momenta and Sandoz. Glatopa is the first AP-rated substitutable generic indicated for the treatment of patients with relapsing-forms of multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration.
Under the terms of its partnershipagreement with Sandoz, Momenta will receive a $10.0 million milestone payment upon first commercial sale. Momenta is also eligible to receive up to $120 million in remaining milestone payments upon the achievement of certain U.S. commercial an
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a complex drug comprising of a synthetic mixture of polypeptide chains for the treatment of patients with relapsing-remitting multiple sclerosis.
Omnicom Group Inc. (NYSE:OMC), ended its Thursday’s trading session with -0.77% loss, and closed at $69.36.
While the media comments on AutoNation’s 10 millionth car sale and $20 million ad campaign with Zimmerman Advertising in recognition of the benchmark, it’s time to put the microscope to over 15 years of partnership between the nation’s largest auto retailer and Omnicom Group Inc. (OMC)’s retail growth machine. Mutual ambition and commitment to results has meant not only an enduring professional relationship, but the generation of comprising success through a period of transition for the advertising industry and a protracted economic downturn.
Since AutoNation partnered with Zimmerman 15+ years ago, the days of simple TV, radio and print ads have fully evolved into much more. While AutoNation continued to buy up local and regional dealerships around the country, Zimmerman paid close attention to retail trends and expanded to integrate their agency for the changing landscape.
The launch of the largest ad campaign in AutoNation history follows noteworthy milestones for both client and agency. While AutoNation made a bold move towards becoming a national retail chain in 2013 by replacing all localized brand names throughout the country with the company’s corporate moniker, Zimmerman invested and accomplished construction on a new headquarters for their fast-growing team and client roster; moving into the only state-of-the-art advertising hub of its kind in the nation.
Omnicom Group Inc., together with its subsidiaries, operates as an advertising, marketing, and corporate communications services company in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It offers services in advertising, customer relationship management, public relations, and specialty communications areas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
